重组人粒细胞刺激因子临床应用安全性评价与合理用药  

Safety Evaluation and Rational Use of rhG- CSF in Clinical Application

作　　者：邓小军[1] 徐蜀远[1] 杨丽萍[1] 

机构地区：[1]四川省自贡市第三人民医院,四川自贡643020

出　　处：《中国药业》2016年第19期9-12,共4页China Pharmaceuticals

摘　　要：目的探讨重组人粒细胞刺激因子(rh G-CSF)临床应用中的安全性,为临床合理用药提供参考。方法搜索数据库国内外有关rhG-CSF临床应用中不良反应的相关文献,并进行归纳分析。结果 rhG-CSF常见不良反应主要包括发热、肌痛、乏力、流感样症状、皮疹、注射部位反应等,一般较轻微,无需特殊处理;严重不良反应有休克、急性肾衰竭、成人呼吸窘迫综合征和间质性肺炎等,需停药和急救,但较少见。结论 rhG-CSF多年来的临床实践和相关临床研究证实其具有良好的安全性,但药品说明书罗列及相关文献报道的一些严重不良反应需引起临床充分重视,用药前详细询问过敏史,用药后密切观察,防范严重不良反应的发生,并积极处理,使发生后的损害后果降低到最小。Objective To investigate the safety of recombinant human granulocyte colony stimulating factor （ rhG-CSF ） in clinical appli-cation, to provide reference for the rational drug use in the clinic. Methods Related literature was searched in Chinese and internation-al databases on rhG-CSF clinical adverse reactions, and then classified analysis was conducted. Results The common adverse reactions of rhG-CSF included fever, myalgias, fatigue, flu like symptoms, rash, and injection site reactions, all of which were generally mild and needed no special treatment;serious adverse reactions such as shock, acute renal failure, adult respiratory distress syndrome and intersti-tial pneumonia required to stop medication and emergency treatment, but this was rather rare. Conclusion Clinical practice and related clinical research of rhG-CSF for many years shows that it has good safety, but some serious adverse reactions reported in the literature and related instructions listed should also cause clinical attention. Before treatment, we should ask in detail about the history of allergies and make close observation after treatment to prevent the occurrence of serious adverse reactions;if occurs, actively deal with it to re-duce the damage to the minimum.

关 键 词：重组人粒细胞刺激因子 安全性评价 合理用药 

分 类 号：R969.3[医药卫生—药理学] R977.6[医药卫生—药学]